CoChat

Substance abuse and movement disorders

Brust, John C.M. · 2010 · Movement Disorders
Cited by 57

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

An array of movement disorders is associated with ethanol, illicit drugs, and tobacco. Heavy ethanol users experience withdrawal tremor and, less often, withdrawal parkinsonism, chorea, and myoclonus. Asterixis is a feature of hepatic failure. On the other hand, ethanol can ameliorate essential tremor and myoclonus‐dystonia. Among opioid drugs, meperidine can precipitate myoclonus. Severe parkinsonism affected users of a synthetic meperidine analog contaminated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine. Spongiform leukoencephalopathy, sometimes with chorea and myoclonus, occurred in inhalers of heroin vapor (chasing the dragon). Psychostimulants including cocaine acutely cause stereotypies and dyskinesias. Phencyclidine toxicity causes myoclonus. Tobacco use, on the other hand, protects against Parkinson's disease. Clinicians need to consider substance abuse in patients with unexplained movement disorders. © 2010 Movement Disorder Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.22599

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 174

  1. Brust JCM, 2004, Neurological aspects of substance abuse, 334
  2. 10.1212/WNL.40.5.741 · DOI
  3. 10.1136/jnnp.28.6.529 · DOI
  4. LeFebvre‐D'Amour M, 1978, Tremor in alcoholic patients, Prog Clin Neurophysiol, 6, 160
  5. 10.1212/WNL.35.11.1660 · DOI · Paper page
  6. 10.1056/NEJM198510103131501 · DOI · Paper page
  7. 10.1016/S0140-6736(89)90842-8 · DOI · Paper page
  8. Kominger C, 2003, Gamma‐hydroxybutyric acid in the treatment of alcohol withdrawal syndrome in patients admitted to hospital, Acta Med Austriaca, 30, 83
  9. 10.1016/S0733-8619(18)30143-9 · DOI
  10. 10.1001/archneur.1992.00530310088016 · DOI
  11. 10.1002/ana.410090117 · DOI
  12. 10.1002/ana.410120307 · doi:10.1002/ana.410120307
  13. 10.1111/j.1360-0443.1988.tb00492.x · doi:10.1111/j.1360-0443.1988.tb00492.x
  14. Shen WW, 1984, Extrapyramidal symptoms associated with alcohol withdrawal, Biol Psychiatry, 19, 1037
  15. 10.1002/mds.870050109 · doi:10.1002/mds.870050109
  16. Fornazzari L, 1982, Transient choreiform dyskinesias during alcohol withdrawal, Can J Neurol Sci, 9, 89, 10.1017/S0317167100043742 · DOI
  17. 10.1136/bmj.4.5730.278 · doi:10.1136/bmj.4.5730.278
  18. 10.1111/j.1471-4159.1977.tb06522.x · DOI
  19. 10.1007/BF00431699 · DOI
  20. Lutz EG, 1976, Neuroleptic‐induced akathesia and dystonia triggered by alcohol, JAMA, 236, 2422, 10.1001/jama.1976.03270220042034 · DOI
  21. 10.3109/00952999009001572 · DOI
  22. 10.1097/00007611-198308000-00028 · DOI
  23. Adams RD, 1953, The neurological disorder associated with liver disease, Res Publ Assoc Res Nerv Ment Dis, 32, 198
  24. 10.1136/jnnp.45.9.857-a · doi:10.1136/jnnp.45.9.857-a
  25. Basile AS, 1991, The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine ligands, Pharmacol Rev, 43, 27, 10.1016/S0031-6997(25)06659-1 · DOI
  26. 10.1023/A:1011658311004 · doi:10.1023/a:1011658311004
  27. 10.1139/y82-082 · DOI
  28. 10.1002/ana.410390515 · DOI · Paper page
  29. 10.1002/mds.10553 · DOI
  30. 10.1212/WNL.33.8.1074 · DOI · Paper page
  31. 10.1176/ajp.139.11.1471 · DOI
  32. 10.1002/mds.20230 · DOI
  33. 10.1212/WNL.59.8.1187 · DOI
  34. 10.1212/01.WNL.0000073142.40185.C1 · doi:10.1212/01.wnl.0000073142.40185.c1
  35. 10.1212/WNL.56.9.1213 · doi:10.1212/wnl.56.9.1213
  36. 10.1007/s100720070053 · doi:10.1007/s100720070053
  37. 10.1212/WNL.58.2.242 · DOI
  38. 10.1002/mds.20452 · doi:10.1002/mds.20452
  39. 10.1002/mds.870110629 · doi:10.1002/mds.870110629
  40. 10.1002/mds.20150 · doi:10.1002/mds.20150
  41. 10.1007/s004150050116 · doi:10.1007/s004150050116
  42. 10.1111/j.1528-1157.1996.tb00579.x · DOI
  43. 10.1024/0040-5930.57.4.241 · DOI
  44. 10.1007/s00406-002-0371-8 · DOI
  45. 10.1002/mds.10363 · doi:10.1002/mds.10363
  46. 10.1002/ana.410020405 · doi:10.1002/ana.410020405
  47. 10.1001/jama.1976.03270220042034 · DOI
  48. 10.5694/j.1326-5377.1981.tb132069.x · doi:10.5694/j.1326-5377.1981.tb132069.x
  49. 10.1136/jnnp.65.3.370 · doi:10.1136/jnnp.65.3.370
  50. Gallinberti L, 2000, Gamma‐hydroxybutyric acid in the treatment of alcohol and heroin dependence, Alcohol, 20, 257, 10.1016/S0741-8329(99)00089-0 · DOI
  51. 10.1002/mds.20605 · DOI
  52. 10.1016/S0736-4679(99)00163-8 · DOI
  53. 10.1097/00004311-196900710-00007 · DOI
  54. 10.7326/0003-4819-90-3-361 · DOI
  55. 10.1176/appi.ajp.158.8.1330-a · DOI
  56. 10.1016/S0379-0738(99)00040-7 · DOI
  57. 10.1016/S0303-8467(97)00088-7 · DOI
  58. 10.1046/j.1360-0443.1999.94343113.x · doi:10.1046/j.1360-0443.1999.94343113.x
  59. Miller JM, 2006, Anhedonia after a selective bilateral lesion of the globus pallidus, Am J Psychiatry, 163, 786, 10.1176/ajp.2006.163.5.786 · DOI
  60. 10.1097/00002826-199903000-00004 · doi:10.1097/00002826-199903000-00004
  61. 10.1007/s00415-005-0760-9 · doi:10.1007/s00415-005-0760-9
  62. 10.1136/bmj.299.6692.150 · DOI
  63. 10.7326/0003-4819-98-4-548 · doi:10.7326/0003-4819-98-4-548
  64. 10.1002/ana.410140520 · doi:10.1002/ana.410140520
  65. 10.1002/ana.410130213 · DOI · Paper page
  66. 10.1097/00004714-198109000-00009 · doi:10.1097/00004714-198109000-00009
  67. 10.1345/aph.1C091 · DOI
  68. 10.1097/00000542-200306000-00033 · DOI
  69. 10.1097/00045391-200201000-00010 · DOI · Paper page
  70. 10.1007/BF03020183 · DOI
  71. 10.1212/WNL.32.6.623 · doi:10.1212/wnl.32.6.623
  72. 10.2165/00003495-198326010-00004 · DOI
  73. 10.1056/NEJM198502213120809 · doi:10.1056/nejm198502213120809
  74. 10.1176/appi.neuropsych.15.1.116 · doi:10.1176/appi.neuropsych.15.1.116
  75. 10.1001/archneur.1980.00500600075016 · doi:10.1001/archneur.1980.00500600075016
  76. 10.1055/s-2007-979316 · doi:10.1055/s-2007-979316
  77. 10.1001/archneur.1981.00510110097023 · doi:10.1001/archneur.1981.00510110097023
  78. 10.1159/000117618 · doi:10.1159/000117618
  79. 10.1016/S0095-5108(18)30081-2 · DOI
  80. 10.1126/science.6823561 · DOI · Paper page
  81. 10.1212/WNL.35.7.949 · DOI · Paper page
  82. 10.1038/317246a0 · DOI · Paper page
  83. 10.1016/0306-4522(91)90180-V · DOI · Paper page
  84. 10.1016/S1566-2772(01)00019-6 · DOI · Paper page
  85. 10.1002/ana.10191 · DOI · Paper page
  86. 10.1016/S0140-6736(82)90101-5 · DOI · Paper page
  87. 10.1007/s003300050467 · doi:10.1007/s003300050467
  88. 10.1212/WNL.53.8.1765 · DOI
  89. 10.1259/bjr/61535842 · DOI
  90. 10.1002/mds.20158 · doi:10.1002/mds.20158
  91. 10.1016/j.crad.2007.07.021 · DOI
  92. 10.1007/s004150050469 · doi:10.1007/s004150050469
  93. 10.1016/0140-6736(92)92268-K · doi:10.1016/0140-6736(92)92268-k
  94. 10.1038/sj.mp.4000575 · DOI
  95. 10.1007/BF00404607 · DOI · Paper page
  96. 10.1136/jnnp.44.8.728 · doi:10.1136/jnnp.44.8.728
  97. 10.1016/0735-6757(88)90050-2 · DOI
  98. 10.1034/j.1600-0404.2003.02086.x · doi:10.1034/j.1600-0404.2003.02086.x
  99. 10.1212/WNL.24.4.312 · DOI
  100. 10.1007/BF00414035 · DOI
  101. 10.1111/j.1469-8749.1974.tb02715.x · DOI · Paper page
  102. 10.1001/archneur.1977.00500220064011 · DOI · Paper page
  103. 10.1192/bjp.143.3.300 · DOI
  104. 10.1056/NEJM196806202782502 · DOI · Paper page
  105. 10.1254/jphs.92.178 · DOI · Paper page
  106. 10.1093/brain/awh046 · DOI · Paper page
  107. 10.1056/NEJMoa072488 · DOI · Paper page
  108. Rylander G, 1972, Psychosis and the punding and choreiform syndromes in addictions to central stimulant drugs, Psychiatry Neurol Neurochir, 75, 203
  109. 10.1212/WNL.44.4.751 · doi:10.1212/wnl.44.4.751
  110. 10.1016/S0006-3223(98)00238-8 · doi:10.1016/s0006-3223(98)00238-8
  111. 10.1136/jnnp.52.12.1447-a · doi:10.1136/jnnp.52.12.1447-a
  112. 10.1016/0376-8716(93)90010-N · DOI
  113. 10.1016/S0196-0644(89)80111-8 · DOI
  114. 10.1016/0002-9343(90)90484-U · DOI · Paper page
  115. Rebischung D, 1990, Dystonic movements associated with cocaine use, Ann Neurol, 28, 267
  116. 10.1212/WNL.40.5.863 · doi:10.1212/wnl.40.5.863
  117. 10.1016/S0196-0644(05)80951-5 · doi:10.1016/s0196-0644(05)80951-5
  118. 10.1212/WNL.39.7.996-a · DOI
  119. 10.1097/00007611-199710000-00017 · doi:10.1097/00007611-199710000-00017
  120. 10.1016/S0735-6757(97)90198-4 · doi:10.1016/s0735-6757(97)90198-4
  121. 10.1212/WNL.56.7.964 · doi:10.1212/wnl.56.7.964
  122. 10.1212/WNL.41.10.1670 · DOI
  123. 10.1016/S0140-6736(86)91478-9 · DOI
  124. 10.1056/NEJM198608073150616 · DOI
  125. 10.1212/WNL.40.6.999 · doi:10.1212/wnl.40.6.999
  126. 10.1002/ana.410230431 · DOI
  127. 10.1111/j.1530-0277.1996.tb01111.x · DOI
  128. 10.1001/jama.258.6.780 · DOI
  129. 10.1080/02791072.1986.10472367 · DOI
  130. Kalant H, 2001, The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs, Can Med Assoc J, 165, 917
  131. 10.1007/s001340050920 · doi:10.1007/s001340050920
  132. 10.1007/s00101-002-0433-3 · doi:10.1007/s00101-002-0433-3
  133. Battaglia G, 1987, 3,4‐Methylenedioxymethamphetamine and 3,4‐methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine‐labelled serotonin uptake sites, J Pharmacol Exp Ther, 242, 911, 10.1016/S0022-3565(25)39191-3 · DOI · Paper page
  134. Ricaurte GA, 1988, 3,4‐Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates, JAMA, 260, 51, 10.1001/jama.1988.03410010059035 · DOI · Paper page
  135. 10.1056/NEJM199905063401817 · doi:10.1056/nejm199905063401817
  136. 10.1056/NEJMc030208 · doi:10.1056/nejmc030208
  137. 10.1002/mds.10623 · DOI
  138. 10.1002/mds.10643 · DOI
  139. 10.1126/science.1074501 · DOI · Paper page
  140. 10.1126/science.301.5639.1454b · doi:10.1126/science.301.5639.1454b
  141. 10.1523/JNEUROSCI.23-27-09107.2003 · DOI · Paper page
  142. 10.1007/BF00421258 · DOI
  143. 10.1007/s002130050848 · DOI · Paper page
  144. 10.1159/000112901 · DOI · Paper page
  145. 10.1002/ana.410130616 · DOI · Paper page
  146. 10.1007/BF00314410 · DOI
  147. 10.1212/01.WNL.0000118203.67138.3E · DOI · Paper page
  148. 10.1007/BF00408109 · DOI
  149. 10.1080/105504901750160529 · DOI · Paper page
  150. 10.1111/j.1360-0443.1984.tb00267.x · doi:10.1111/j.1360-0443.1984.tb00267.x
  151. 10.1212/WNL.33.10.1337 · DOI
  152. 10.1093/qjmed/93.10.655 · DOI
  153. 10.1093/brain/121.10.1903 · DOI
  154. 10.1016/S0196-0644(81)80047-9 · DOI · Paper page
  155. 10.1016/0149-7634(84)90006-X · doi:10.1016/0149-7634(84)90006-x
  156. Salomon ME, 1998, Goldfrank's toxicologic emergencies, 1145
  157. 10.1002/ana.10028 · DOI · Paper page
  158. 10.1002/ana.10315 · DOI
  159. 10.1212/WNL.58.4.581 · DOI · Paper page
  160. 10.1212/WNL.52.1.115 · DOI · Paper page
  161. 10.1016/S0161-813X(02)00036-0 · DOI
  162. 10.1212/WNL.57.6.1032 · DOI
  163. 10.1038/379733a0 · DOI · Paper page
  164. 10.1212/WNL.58.9.1381 · DOI
  165. 10.1212/WNL.50.5.1458 · DOI
  166. 10.1016/0006-8993(94)91593-8 · DOI
  167. 10.1046/j.1471-4159.1998.71062439.x · DOI · Paper page
  168. 10.1016/0024-3205(94)00839-6 · DOI
  169. 10.1002/1531-8257(200009)15:5<1014::AID-MDS1041>3.0.CO;2-O · doi:10.1002/1531-8257(200009)15:5<1014::aid-mds1041>3.0.co;2-o
  170. 10.1016/S1474-4422(03)00529-5 · DOI · Paper page
  171. 10.1002/mds.20045 · DOI · Paper page
  172. 10.1097/00002826-200105000-00009 · DOI · Paper page
  173. 10.1212/01.wnl.0000184487.72289.f0 · DOI · Paper page
  174. Weed MR, 1995, The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys, J Pharmacol Exp Ther, 275, 1367, 10.1016/S0022-3565(25)12193-9 · DOI · Paper page

Cited by

Metadata

Authors
Brust, J. C. M.
Venue
Movement Disorders
Publisher
Wiley
Published
2010-08-18
Volume
25
Issue
13
Pages
2010-2020
ISSN
  • 0885-3185
  • 1531-8257
Cited by
57
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.